% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hlevnjak:305611,
      author       = {M. Hlevnjak and S. Heublein and V. Thewes$^*$ and L.
                      Wagener and C. Pixberg and C. Fremd and L. Michel and C.
                      Maurer and L. Buschhorn and N. Dikow and F. Feng$^*$ and S.
                      Fröhling$^*$ and C. Herold-Mende and S. Hirsch$^*$ and C.
                      Hong$^*$ and D. Hübschmann$^*$ and L. Jassowicz$^*$ and P.
                      Kozyulina and K. Pfütze$^*$ and R. F. Schlenk and H.-P.
                      Sinn and K. Smetanay and C. Springfeld and A. Stenzinger and
                      C. Wagner and S. Wolf$^*$ and A. Trumpp$^*$ and D. Jäger
                      and O. Zivanovic and M. Zapatka$^*$ and A. Schneeweiss and
                      P. Lichter$^*$},
      title        = {{D}elivering precision oncology in metastatic breast
                      cancer: {C}linical impact of comprehensive genomic
                      profiling-{T}he {CATCH} experience.},
      journal      = {International journal of cancer},
      volume       = {nn},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2025-02261},
      pages        = {nn},
      year         = {2025},
      note         = {DKFZ-ZMBH Alliance / #LA:B060# / epub},
      abstract     = {CATCH is a prospective precision oncology registry trial
                      that exploits whole-genome/exome- and RNA-sequencing to
                      enable actionable biomarker detection in metastatic breast
                      cancer (mBC) patients of any subtype. We herein report
                      long-term follow-up of the first 558 patients consecutively
                      recruited into CATCH in a monocentric setting between June
                      2017 and October 2021. Main outcome measures were the rate
                      of implementation of molecular tumor board (MTB) recommended
                      treatments and treatment response as assessed by disease
                      control rate, objective response rate and PFS ratio. Out of
                      the recruited patients, 412 $(54.9\%$ HR+/HER2-, $31.3\%$
                      TNBC, $6.8\%$ HR-/HER2+ and $7.0\%$ HR+/HER2+) were reviewed
                      in the MTB. An appropriate molecularly guided anti-cancer
                      treatment as recommended by MTB was implemented in 183
                      $(44.4\%)$ patients. Gene expression and computationally
                      derived composite biomarkers further expanded treatment
                      options in up to every second patient as compared to genomic
                      sequencing data alone. The outcome was assessed in 152
                      patients and showed a Disease Control Rate (DCR) of $58.6\%$
                      and an Objective Response Rate (ORR) of $27.0\%.$ One in
                      three patients $(32.8\%)$ showed at least a $50\%$ longer
                      PFS with molecularly guided therapy compared to the previous
                      standard therapy. Notably, $86.4\%$ of the MTB-driven
                      implementations were off-label. CATCH highlights the impact
                      of whole-genome/exome in combination with RNA sequencing to
                      detect clinically relevant biomarkers in mBC. Omics-guided
                      targeted therapy in a real-world setting allows high
                      treatment implementation rates yielding outcome benefit for
                      one-third of the patients.},
      keywords     = {breast cancer (Other) / precision oncology (Other) /
                      real‐world study (Other) / whole genome sequencing (Other)
                      / whole transcriptome sequencing (Other)},
      cin          = {B060 / B340 / HD01 / B062 / W190 / A010},
      ddc          = {610},
      cid          = {I:(DE-He78)B060-20160331 / I:(DE-He78)B340-20160331 /
                      I:(DE-He78)HD01-20160331 / I:(DE-He78)B062-20160331 /
                      I:(DE-He78)W190-20160331 / I:(DE-He78)A010-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41170836},
      doi          = {10.1002/ijc.70208},
      url          = {https://inrepo02.dkfz.de/record/305611},
}